Kyowa Kirin CoKYKOF 82 EBITDA Margin % is 31.98% as of Dec. 2025, which is 40% above its 10-year median of 22.92. GuruFocus rates KYKOF with a GF Score™ of 82/100 and a GF Value™ of $17.92 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 955 Drug Manufacturers companies, Kyowa Kirin Co ranks better than 76.65% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Kyowa Kirin Co's EBITDA for the
three
months ended in Dec. 2025 was $302 Mil. Kyowa Kirin Co's Revenue for the
three
months ended in Dec. 2025 was $945 Mil. Therefore, Kyowa Kirin Co's EBITDA margin for the quarter that ended in Dec. 2025 was 31.98%.
Kyowa Kirin Co (OTCPK:KYKOF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Kyowa Kirin Co EBITDA Margin % Related Terms
Kyowa Kirin Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Kyowa Kirin Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kyowa Kirin Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyowa Kirin Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kyowa Kirin Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Kyowa Kirin Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyowa Kirin Co (KYKOF) has a EBITDA Margin % of 31.98% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kyowa Kirin Co and its competitors. This is 40% above median its historical median of 22.92. Over the past decade, Kyowa Kirin Co's EBITDA Margin % has ranged from 19.27 to 31.11. According to the industry distribution chart, Kyowa Kirin Co ranks #223 out of 955 companies in the Drug Manufacturers industry, placing it in the top 23.4%.
Is Kyowa Kirin Co's EBITDA Margin % too high?
Kyowa Kirin Co's current EBITDA Margin % of 31.98% is 40% above median its 10-year median of 22.92. Over the past 10 years, this metric has ranged from a low of 19.27 to a high of 31.11. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Kyowa Kirin Co's value of 31.98% is 157.1% above this industry median. Based on the distribution chart, Kyowa Kirin Co ranks #223 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kyowa Kirin Co has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kyowa Kirin Co's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kyowa Kirin Co ranks #223 out of 955 companies for EBITDA Margin %. This places Kyowa Kirin Co in the top 23% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.44. Kyowa Kirin Co's value of 31.98% is 157.1% above this benchmark. Historically, Kyowa Kirin Co's own EBITDA Margin % has ranged from 19.27 to 31.11 over the past decade. While the company's 10-year median is 22.92 vs. the industry median of 12.44, Kyowa Kirin Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kyowa Kirin Co's current EBITDA Margin % of 31.98% is 157.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kyowa Kirin Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyowa Kirin Co's current EBITDA Margin % is 31.98%, which is 40% above median its own 10-year median of 22.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyowa Kirin Co stock overvalued right now?
Based on GuruFocus' analysis, Kyowa Kirin Co (KYKOF) is currently considered Modestly Undervalued. The stock's GF Value™ is $17.92, compared to a current price of $14.43 — trading 19.5% below its estimated fair value. The current EBITDA Margin % is 31.98%, which is 40% above median its 10-year median of 22.92 and 157.1% above the Drug Manufacturers industry median of 12.44. Kyowa Kirin Co's overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Kyowa Kirin Co (KYKOF), the current EBITDA Margin % is 31.98% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyowa Kirin Co (KYKOF) Overvalued in 2026?
Based on GuruFocus' analysis, Kyowa Kirin Co stock appears to be undervalued.
The current stock price of $14.43 is trading 19.5% below its estimated GF Value™ of $17.92.
GuruFocus considers Kyowa Kirin Co to be Modestly Undervalued.
Key valuation signals for KYKOF:
EBITDA Margin %: 31.98% (40% above median its 10-year median of 22.92)
GF Value™: $17.92 vs. price of $14.43 (19.5% below fair value)
Industry Position: 157.1% above the Drug Manufacturers median (#223 of 955)
No single metric tells the full story. See the KYKOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyowa Kirin Co Ltd is engaged in research, development, manufacturing, sales, import and export of prescription pharmaceuticals. Its products include KHK4083/AMG 451, rocatinlimab; ziftomenib; OTL-203 KK8398, infigratinib; KHK4951, tivozanib; OTL-201; KK4277; KK2260; KK2269; KK2845; and KK8123.
82GF Score
Get the complete analysis for KYKOF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KYKOF has been successfully added to your 
